Time trends in systemic treatment for patients with metastatic prostate cancer: a national cohort study

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Norway CRo. Cancer in Norway 2019 - Cancer incidence, mortality, survival and prevalence in Norway. 2020.
   Google Scholar
• Pagliarulo V, Bracarda S, Eisenberger MA, et al. Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol. 2012;61(1):11–25. doi: 10.1016/j.eururo.2011.08.026.
   PubMed Web of Science ®Google Scholar
• Fossa SD, Jacobsen AB, Ginman C, et al. Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study. Eur Urol. 2007;52(6):1691–1698. doi: 10.1016/j.eururo.2007.01.104.
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–1512. doi: 10.1056/NEJMoa040720.
   PubMed Web of Science ®Google Scholar
• James ND, Spears MR, Clarke NW, et al. Survival with newly diagnosed metastatic prostate cancer in the “docetaxel era”: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019). Eur Urol. 2015;67(6):1028–1038. doi: 10.1016/j.eururo.2014.09.032.
   PubMed Web of Science ®Google Scholar
• Sweeney CJ, Chen Y-H, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–746. doi: 10.1056/NEJMoa1503747.
   PubMed Web of Science ®Google Scholar
• Chowdhury S, Bjartell A, Lumen N, et al. Real-world outcomes in first-line treatment of metastatic castration-resistant prostate cancer: the prostate cancer registry. Target Oncol. 2020;15(3):301–315. doi: 10.1007/s11523-020-00720-2.
   PubMed Web of Science ®Google Scholar
• Shayegan B, Wallis CJD, Malone S, et al. Real-world use of systemic therapies in men with metastatic castration resistant prostate cancer (mCRPC) in Canada. Urol Oncol. 2022;40(5):192.e1–e9. doi: 10.1016/j.urolonc.2022.01.009.
   PubMed Web of Science ®Google Scholar
• Wen L, Valderrama A, Costantino ME, et al. Real-world treatment patterns in patients with castrate-resistant prostate cancer and bone metastases. Am Health Drug Benefits. 2019;12(3):142–149.
   PubMed Web of Science ®Google Scholar
• Anton A, Pillai S, Semira MC, et al. Real-world first-line systemic therapy patterns in metastatic castration-resistant prostate cancer. BJUI Compass. 2022;3(3):205–213. doi: 10.1002/bco2.129.
   PubMedGoogle Scholar
• Lavoie JM, Zou K, Khalaf D, et al. Clinical effectiveness of docetaxel for castration-sensitive prostate cancer in a real-world population-based analysis. Prostate. 2019;79(3):281–287. doi: 10.1002/pros.23733.
   PubMed Web of Science ®Google Scholar
• Isaksson J, Green H, Papantoniou D, et al. Real-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer. World J Clin Oncol. 2021;12(11):1009–1022. doi: 10.5306/wjco.v12.i11.1009.
   PubMed Web of Science ®Google Scholar
• Lendorf ME, Petersen PM, Svendsen AS, et al. Effectiveness of docetaxel for metastatic hormone-sensitive prostate cancer in clinical practice. Eur Urol Open Sci. 2021;24:25–33. doi: 10.1016/j.euros.2020.12.006.
   PubMedGoogle Scholar
• Hernes E, Kyrdalen A, Kvåle R, et al. Initial management of prostate cancer: first year experience with the norwegian national prostate cancer registry. BJU Int. 2010;105(6):805–811; discussion 811. doi: 10.1111/j.1464-410X.2009.08834.x.
   PubMed Web of Science ®Google Scholar
• NYE METODER https://nyemetoder.no/en.
   Google Scholar
• de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005. doi: 10.1056/NEJMoa1014618.
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–1197. doi: 10.1056/NEJMoa1207506.
   PubMed Web of Science ®Google Scholar
• Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–433. doi: 10.1056/NEJMoa1405095.
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138–148. doi: 10.1056/NEJMoa1209096.
   PubMed Web of Science ®Google Scholar
• Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–223. doi: 10.1056/NEJMoa1213755.
   PubMed Web of Science ®Google Scholar
• de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–1154. doi: 10.1016/S0140-6736(10)61389-X.
   PubMed Web of Science ®Google Scholar
• Multiple-Imputation Reference Manual, version 18: Stata Press; 2021. 388 p.
   Google Scholar
• A language and environment for statistical computing. R foundation for statistical computing. Vienna, Austria: R Core Team; 2022.
   Google Scholar
• Wickham H, Fr Henry L. Müller K dplyr: A grammar of data manipulation. 2022 [cited 2022 Dec 5]. Avaialble: https://dplyr.tidyverse.org., https://github.com/tidyverse/dplyr.
   Google Scholar
• Allaire JE, Gandrud C, Kuo K, et al. Yetman CJ networkD3: D3 JavaScript Network Graphs [cited 2022 Dec 5]. from R. R package version 0.4. https://CRAN.R-project.org/package=networkD3. 2017
   Google Scholar
• Coviello V, Boggess MA. Cumulative incidence estimation in the presence of competing risks. The Stata Journal. 2004;4(2):103–112. doi: 10.1177/1536867X0400400201.
   Web of Science ®Google Scholar
• Lissbrant IF, Garmo H, Widmark A, et al. Population-based study on use of chemotherapy in men with castration resistant prostate cancer. Acta Oncol. 2013;52(8):1593–1601. doi: 10.3109/0284186X.2013.770164.
   PubMed Web of Science ®Google Scholar
• Vigneswaran HT, Warnqvist A, Andersson TML, et al. Real world treatment utilization patterns in patients with castration-resistant prostate cancer. Scand J Urol. 2021;55(4):299–306. doi: 10.1080/21681805.2021.1936626.
   PubMed Web of Science ®Google Scholar
• Westgeest HM, Uyl-de Groot CA, van Moorselaar RJA, et al. Differences in trial and real-world populations in the dutch castration-resistant prostate cancer registry. Eur Urol Focus. 2018;4(5):694–701. doi: 10.1016/j.euf.2016.09.008.
   PubMedGoogle Scholar
• Penson DF, Lin DW, Karsh L, et al. Treatment registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET): a methodology for real-world evidence and research. Future Oncol. 2016;12(23):2689–2699. doi: 10.2217/fon-2016-0298.
   PubMed Web of Science ®Google Scholar
• James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163–1177. doi: 10.1016/S0140-6736(15)01037-5.
   PubMed Web of Science ®Google Scholar